Compare KLA Corp. (KLAC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Zoetis Inc — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: KLA Corp. is far larger — about 8.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Zoetis Inc for 70 Days on average.
| KLAC | ZTS | |
|---|---|---|
Market Cap | $256.72B | $30.20B |
Volume | 9,970,753 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $301.71 | $147.53 |
52-Week Low | $98.28 | $69.09 |
Typical Hold Time | 60 Days | 70 Days |
Enterprise Value | $257.97B | $37.76B |
Dividend Yield | 0.47% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing minimal daily movement with strong fundamental performance. The stock maintains bullish technical signals with support at $193 and resistance at $201. Recent earnings consistently beat expectations, with Q2 2026 EPS of $1.05 exceeding the $1.00 forecast. The company demonstrates robust profitability with 35.57% net income margin and 87.5% ROE, supported by AI-driven semiconductor equipment demand and a $12.57 billion backlog.
Outlook remains positive with analyst consensus target of $223.88 offering 14% upside potential. Key opportunities include AI infrastructure growth and advanced packaging demand, while risks involve competitive pressure from Applied Materials and ASML, along with execution challenges in meeting ambitious $26 billion revenue target by 2030. Institutional ownership trends show continued confidence with recent acquisitions by Envestnet Portfolio Solutions.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
